IIT Bombay Device Screens Anaemia and Sickle Cell Cheaply

Researchers at the Indian Institute of Technology (IIT) Bombay have engineered a breakthrough, low-cost diagnostic tool capable of screening for anaemia and sickle cell disease from a single drop of blood. Spearheaded by Prof. Mahesh Tirumkudulu and his team from the Department of Chemical Engineering, the innovation tackles persistent healthcare hurdles in resource-limited regions by pairing fluid mechanics with accessible clinical screening.

Announced on Friday, the patented point-of-care approach utilizes the physical length of a blood smear—specifically the precise distance a blood droplet spreads across a standard glass slide—to detect medical abnormalities. By standardizing the smearing process through an automated mechanical device, the research team unlocked a reliable method to evaluate blood viscosity without relying on expensive laboratory machinery or specialized clinical expertise.

Core Development Breakdown

At the heart of this medical innovation is a deceptively simple premise: analyzing how a drop of blood behaves when deposited and spread across a flat surface. Dr. Mahrukh Mir, a former PhD scholar in Prof. Tirumkudulu’s laboratory and the lead author of the study, noted that the technique was designed explicitly for regions where conventional diagnostic laboratories remain out of reach. The physical hardware requires nothing more than a pipette, clean glass slides, an inexpensive chemical, specific vials for sickling treatment, and a ruler or basic imaging device to quantify smear length.

This development arrives as public health researchers increasingly focus on early diagnostics for conditions that frequently go undetected, intersecting with broader investigations into how genetic profiles influence common health vulnerabilities across diverse populations. By cutting down equipment overhead, the IIT Bombay prototype removes financial and logistical barriers that routinely delay life-saving interventions in rural clinics.

Technological and Fluid Dynamic Mechanism

The core scientific breakthrough began with a fundamental physics inquiry into the spreading dynamics of fluid drops. Prof. Tirumkudulu explained that their initial focus centered entirely on understanding the mechanics of blood drop expansion before realizing its medical utility. Under controlled, uniform conditions applied by their automated smearing device, human blood exhibits distinct variations in spread length.

Viscosity serves as the primary diagnostic indicator. More viscous blood resists spreading easily, producing a noticeably shorter and thicker smear. Clinical correlations validate this fluid behavior: anaemia diminishes red blood cell concentration and haemoglobin levels, whereas sickle cell disease alters cellular structure by causing red blood cells to become rigid. When exposed to specific chemical treatments included in the kit, sickled cells alter the fluid dynamics further, allowing the user to detect and monitor the disease accurately.

Engineering Architecture and Fluid Physics Mechanics

To fully appreciate the breakthrough achieved by the IIT Bombay team, one must examine the fluid dynamics governing blood as a non-Newtonian fluid. Unlike water, whose viscosity remains constant regardless of shear rate, blood exhibits complex rheological behavior due to the presence of suspended cells, primarily red blood cells (erythrocytes), white blood cells, and platelets. Under standard capillary flow and spreading conditions on a solid substrate, the extent of liquid propagation is dictated by a delicate balance of capillary forces, viscous dissipation, and gravitational effects.

The automated mechanical smearing device engineered by the laboratory standardizes the initial kinetic energy and applied downward force imparted to the blood droplet. By removing the human error inherent in manual wedge-slide smearing techniques, the device ensures that the initial droplet volume and the velocity of the spreading blade remain identical across every test. When normal blood encounters the glass surface, it flows predictably. However, pathological states disrupt this equilibrium. In iron-deficiency anaemia, the reduced volume fraction of erythrocytes (hematocrit) lowers the bulk viscosity of the fluid. Consequently, the capillary-driven spreading front advances farther across the glass slide, resulting in a significantly extended smear length.

Conversely, in sickle cell disease, abnormal hemoglobin (HbS) molecules polymerize under low oxygen or specific chemical stress conditions, forcing the flexible biconcave erythrocytes into rigid, elongated sickle shapes. When these treated blood samples are processed through the device, the altered cellular morphology dramatically changes internal fluid friction. The cells jam and resist flow, shortening the overall smear distance. By quantifying this spatial displacement using a simple linear scale or a smartphone camera paired with basic image-processing algorithms, the device translates complex rheological properties into an actionable, binary clinical metric.

Market Competition and Real-World Socioeconomic Impact

When evaluated against conventional haematology benchmarks, the IIT Bombay device occupies a unique intersection of affordability and accessibility. Standard complete blood count (CBC) analyzers and automated high-performance liquid chromatography (HPLC) systems—the gold standards for diagnosing haemoglobinopathies—frequently cost tens of thousands of dollars, demand uninterrupted electrical grids, require daily calibration fluids, and depend on trained laboratory technicians. These infrastructural requirements render them practically useless in remote community health centers, primary health posts, and mobile medical camps operating in tribal belts.

Enterprise medical device manufacturers typically target urban hospital networks, leaving rural populations reliant on delayed sample transportation to centralized labs. The IIT Bombay innovation directly disrupts this model by decentralizing diagnostics. By slashing capital expenditure per test to mere fractions of a rupee, local frontline health workers can screen entire communities in real time. This blood-viscosity tool delivers actionable local data where centralized testing fails, empowering rural clinics to initiate treatment protocols immediately rather than waiting weeks for lab results.

Chronology, Validation Milestones, and Commercialization Path

The journey from a fundamental physics curiosity to an enterprise-ready medical tool spans several years of rigorous academic research and institutional partnership. The research initiative commenced as an investigation into droplet spreading mechanics within the Department of Chemical Engineering at IIT Bombay. After recognizing the strong correlation between fluid spread length and haematocrit levels, the research team secured patent protection for the mechanical smearing apparatus and diagnostic methodology.

To transition the laboratory prototype into a market-viable product, IIT Bombay licensed the technology to Rheoheme Private Limited, an institutional startup dedicated to scaling point-of-care blood diagnostics. The commercialization roadmap requires navigating strict clinical validation phases to satisfy national regulatory frameworks. To achieve this, Rheoheme and the IIT Bombay researchers established formal collaborative agreements with premier medical research bodies, including the All India Institute of Medical Sciences (AIIMS) in Nagpur and the National Institute for Research in Tribal Health (NIRTH) in Jabalpur, Madhya Pradesh. These institutions are currently conducting multi-center blind trials to benchmark the device’s sensitivity and specificity against established clinical standards across diverse demographic cohorts.

Looking toward future technical milestones, the development team is actively expanding the platform’s diagnostic capabilities. Current laboratory iterations are exploring whether the automated smearing and viscosity-measuring hardware can be adapted to evaluate clotting times and measure blood glucose concentrations. By transforming a single-purpose screening tool into a modular, multi-parameter diagnostic workstation, the initiative aims to fundamentally redefine frontline healthcare delivery across resource-constrained regions globally.

Frequently Asked Questions

How does the IIT Bombay device detect anaemia?

The device uses an automated mechanism to create a uniform blood smear on a glass slide. Anaemia lowers red blood cell concentration and haemoglobin levels, which alters blood viscosity and causes the droplet to spread farther than normal, creating a longer smear.

What equipment is required to perform the test?

The diagnostic procedure is designed to be inexpensive and portable. It requires only a pipette, glass slides, an affordable chemical reagent, treatment vials for sickling, and a basic ruler or digital imaging device to measure the length of the smear.

Who holds the commercial rights to this technology?

The technology has been licensed to Rheoheme Private Limited, an IIT Bombay incubated startup, which is currently collaborating with AIIMS Nagpur and NIRTH Jabalpur for clinical validation and regulatory approval.

How does sickle cell disease affect the physical behavior of the blood sample in this test?

Sickle cell disease causes red blood cells to become rigid and distorted under specific chemical treatments included in the kit. This cellular rigidity increases fluid resistance and internal friction, resulting in a noticeably shorter and thicker blood smear compared to normal samples.

Sources and further reading

• The Hindu: IIT Bombay develops low-cost device to screen for anaemia, sickle cell disease